Bivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention in Patients at High Risk for Bleeding

Abstract

Low/medium-bleeding-risk populations undergoing percutaneous coronary intervention (PCI) show significantly less bleeding with bivalirudin (BIV) than with unfractionated heparin (UFH), but this has not been established for high-risk patients. We performed a randomized double-blind prospective trial comparing efficacy and safety of BIV versus UFH combined with dual antiplatelet therapy during PCI among 100 high-risk patients with non-ST elevation myocardial infarction (NSTEMI) or angina pectoris. The baseline characteristics were similar in both treatment arms. A radial approach was used in 84% of patients with a higher rate in the BIV group (90 vs. 78%, p < 0.05). Study end points were: major and minor bleeding, port-of-entry complications, major adverse cardiac events (MACE) in-hospital, and at long-term follow-up. There was one case of major gastrointestinal bleeding in the BIV group and 7% minor bleeding complications in both categories. Rate of periprocedural myocardial infarction (PPMI) in the BIV group was twice that in the UFH group (20 vs. 10%, p < 0.16). In-hospital MACE rate was higher in BIV patients as well (12 vs. 2%, p = 0.1). By univariate analysis, the femoral approach was the predictor of PPMI and in-hospital MACE. In a multivariate model, the independent predictor of PPMI was previous MI (odds ratio, 7.7; p < 0.0158). PPMI was 49.7 times more likely with the femoral approach plus BIV than the nonfemoral approach plus UFH (p < 0.0021). At 41.5 ± 14 months' follow-up, end points did not significantly differ between the groups. In patients at high risk for bleeding undergoing PCI, BIV was not superior to UFH for bleeding complications, and early and late clinical outcomes.

Keywords

bivalirudin - unfractionated heparin - PCI - bleeding - high-risk patient

• References

• 1 Nasser TK, Mohler III ER, Wilensky RL, Hathaway DR. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol 1995; 18 (11) 609-614
• 2 Ellis SG. Elective coronary angioplasty: technique and complications. In: Topol EJ, ed. Textbook of Interventional Cardiology, 2nd edition. Philadelphia, PA: W.B. Saunders; 1993: 186-207
• 3 Bredlau CE, Roubin GS, Leimgruber PP, Douglas Jr JS, King III SB, Gruentzig AR. In-hospital morbidity and mortality in patients undergoing elective coronary angioplasty. Circulation 1985; 72 (5) 1044-1052
• 4 Green GS, McKinnon CM, Rösch J, Judkins MP. Complications of selective percutaneous transfemoral coronary arteriography and their prevention. A review of 445 consecutive examinations. Circulation 1972; 45 (3) 552-557
• 5 Kelsey SF, Mullin SM, Detre KM , et al. Effect of investigator experience on percutaneous transluminal coronary angioplasty. Am J Cardiol 1984; 53 (12) 56C-64C
• 6 Topol EJ, Califf RM, Weisman HF , et al; The EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343 (8902) 881-886
• 7 Lincoff AM, Tcheng JE, Califf RM , et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999; 99 (15) 1951-1958
• 8 Kastrati A, Mehilli J, Schühlen H , et al; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350 (3) 232-238
• 9 Lincoff AM, Bittl JA, Harrington RA , et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289 (7) 853-863
• 10 Stone GW, McLaurin BT, Cox DA , et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355 (21) 2203-2216
• 11 Kastrati A, Neumann FJ, Mehilli J , et al; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359 (7) 688-696
• 12 Kastrati A, Neumann FJ, Schulz S , et al; ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365 (21) 1980-1989
• 13 Vidi VD, Matheny ME, Agarwal V , et al. Validation of long-term benefits of bivalirudin versus unfractionated heparin in routine clinical practice after percutaneous coronary intervention. Am J Cardiol 2010; 106 (9) 1234-1240
• 14 Verheugt FW, Steinhubl SR, Hamon M , et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv 2011; 4 (2) 191-197
• 15 Hanna EB, Chen AY, Roe MT, Wiviott SD, Fox CS, Saucedo JF. Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 2011; 4 (9) 1002-1008
• 16 Chew DP, Lincoff AM, Gurm H , et al; REPLACE-2 Investigators. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005; 95 (5) 581-585
• 17 Saltzman AJ, Stone GW, Claessen BE , et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv 2011; 4 (9) 1011-1019